On November 18, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Peace Pharmaceutical Co., Ltd., obtained a registration certificate from the Ministry of Health of the Republic of Panama for its methylprednisolone sodium succinate for injection, signifying that the drug can be manufactured and sold in the Panamanian market. In April of this year, the product also obtained a registration certificate from the Ministry of Health of the Dominican Republic, marking a series of successes for the company in its overseas expansion.

Methylprednisolone sodium succinate for injection is a glucocorticoid drug primarily used for anti-infection treatment, immunosuppressive therapy, treatment of hematological diseases and tumors, and treatment of shock. This registration certificate will bring new opportunities for the company's pharmaceutical preparation business to expand into the Panamanian market and will further promote the company's internationalization strategy.

Tianjin Pharmaceutical Group has established a broad and deep market foundation and actively expanded its overseas business. Through participation in international exhibitions, technological cooperation, and market promotion, it has built a certain level of brand recognition in the international market. The company's overseas expansion, from consolidating its advantages in active pharmaceutical ingredients (APIs) to achieving breakthroughs in formulations in emerging markets such as Panama, demonstrates its steady progress from technology to market. Going forward, Tianjin Pharmaceutical Group will focus on both domestic and international markets in both APIs and formulations, striving to unleash its commercial potential.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)